Upstream-Complement Assay-Format Stratification

COMP-021 is invalidated and non-runnable. Its mixed verification tiers, heuristic relevance scores, and inconsistent relationship between inputs, code, and summary cannot support a quantitative range, candidate ranking, uncertainty-collapse claim, or estimate of operative gut potency.

Research conjecture — matched assay formats may sharpen replication planning

Grounded premises: Wu et al. 2015 reported complement inhibition using hemolytic and ELISA formats, and Talsma et al. 2020 tested heparin materials across complement assays that interrogate different pathway contexts (In Vitro; PMC4629277 and PMC7212410). These records establish that assay format is a meaningful experimental variable; they do not establish an intestinally operative potency.

Novel leap: For a candidate selected from its own independently verified evidence, testing one exact material across a preregistered panel of matched complement formats may separate format-specific biology from replication noise and improve the next experiment. No direct evidence establishes that this strategy predicts gout-relevant or gut-luminal activity.

Why it matters: A matched panel could prevent a single assay result from acquiring false precision or candidate privilege while preserving mechanistically interesting leads.

Discriminating observation: Test one exact batch, concentration series, serum source, timing scheme, and positive controls across at least two mechanistically distinct formats plus an MSU-relevant complement readout. Advance the stratification only if the pattern reproduces independently and changes a predeclared experimental decision.

No compound inherits priority from COMP-021. The former COMP-020 is quarantined literature provenance; current authority rests with each reverified, candidate-specific evidence page.